SEC Company Response from PURPLE BIOTECH LTD. (PPBT) (CIK 0001614744) (PPBT) — May 20, 2020
PURPLE BIOTECH LTD. (PPBT) (CIK 0001614744)
Date: May 20, 2020 · CIK: 0001614744 · Accession: 0001213900-20-013056
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-238229
Letter
RE: Kitov Pharma Ltd.
May 20, 2020
By EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street N.E.
Washington, D.C. 20549
Attention: Laura Crotty
Registration Statement on Form F-3
Filed May 13, 2020
Request for Acceleration
File No. 333-238229
Ladies and Gentlemen:
Pursuant to Rule 461 of the Rules and Regulations of the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended, Kitov Pharma Ltd. (the “Company”) hereby requests acceleration of the effective date of the above-mentioned Registration Statement on Form F-3 (the “Registration Statement”) to 3:00 p.m., Eastern Time on May 20, 2020, or as soon thereafter as practicable.
Should any member of the staff of the U.S. Securities and Exchange Commission have any questions or comments with respect to this request, please contact our counsel, Haynes and Boone, LLP, attention: Rick A. Werner, Esq. at (212) 659-4974.
Very truly yours,
Kitov Pharma Ltd.
Show Raw Text
CORRESP
1
filename1.htm
May 20, 2020
By EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street N.E.
Washington, D.C. 20549
Attention: Laura Crotty
RE:
Kitov Pharma Ltd.
Registration Statement on Form F-3
Filed May 13, 2020
Request for Acceleration
File No. 333-238229
Ladies and Gentlemen:
Pursuant to Rule 461 of
the Rules and Regulations of the Securities and Exchange Commission (the “Commission”) under the Securities
Act of 1933, as amended, Kitov Pharma Ltd. (the “Company”) hereby requests acceleration of the effective date
of the above-mentioned Registration Statement on Form F-3 (the “Registration Statement”) to 3:00 p.m., Eastern
Time on May 20, 2020, or as soon thereafter as practicable.
Should
any member of the staff of the U.S. Securities and Exchange Commission have any questions or comments with respect to this request,
please contact our counsel, Haynes and Boone, LLP, attention: Rick A. Werner, Esq. at (212) 659-4974.
Very truly yours,
Kitov Pharma Ltd.
By:
/s/ Isaac
Israel
Isaac
Israel
Chief Executive Officer
cc: Rick
A. Werner, Esq., Haynes and Boone, LLP
Jayun
Koo, Esq., Haynes and Boone, LLP
So
Yung Kang, Esq., Haynes and Boone, LLP